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Association Between Disability Measures and Healthcare
Costs After Initial Treatment for Acute Stroke
Jesse Dawson, MRCP; Jennifer S. Lees, BA; Tou-Pin Chang, BSc; Matthew R. Walters, MD, FRCP;
Myzoon Ali, MRes; Stephen M. Davis, MD, FRACP; Hans-Christoph Diener, MD;
Kennedy R. Lees, MD, FRCP; for the GAIN and VISTA Investigators
Background and Purpose—The distribution of 3-month modified Rankin scale (mRS) scores has been used as an outcome
measure in acute stroke trials. We hypothesized that hospitalization and institutional care home stays within the first 90
days after stroke should be closely related to 90-day mRS, that each higher mRS category will reflect incremental cost,
and that resource use may be less clearly linked to the National Institutes of Health Stroke Scale (NIHSS) or Barthel
index.
Methods—We examined resource use data from the GAIN International trial comparing 90-day mRS with total length of
stay in hospital or other institutions during the first 90 days. We repeated analyses using NIHSS and Barthel index
scores. Relationships were examined by analysis of variance (ANOVA) with Bonferroni contrasts of adjacent score
categories. Estimated costs were based on published Scottish figures.
Results—We had full data from 1717 patients. Length of stay was strongly associated with final mRS (P0.0001). Each
mRS increment from 0 to 1–2 to 3–4 was significant (mean length of stay: 17, 25, 44, 58, 79 days; P0.0005).
Ninety-five percent confidence limits for estimated costs (£) rose incrementally: 2493 to 3412, 3369 to 4479, 5784 to
7008, 7300 to 8512, 10 095 to 11 141, 11 772 to 13 560, and 2623 to 3321 for mRS 0 to 5 and dead, respectively.
Weaker relationships existed with Barthel and NIHSS.
Conclusions—Each mRS category reflects different average length of hospital and institutional stay. Associated costs are
meaningfully different across the full range of mRS outcomes. Analysis of the full distribution of mRS scores is
appropriate for interpretation of treatment effects after acute stroke and more informative than Barthel or NIHSS end
points. (Stroke. 2007;38:1893-1898.)
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The recent paper published by Lees et al in the NewEngland Journal of Medicine on results of the SAINT
trial found that modified Rankin scale (mRS) scores at 90
days were significantly more favorable after acute stroke in
those treated with NXY-059 compared with placebo
(OR1.20, 95% CI1.01 to 1.42).1 The benefit was more
modest than some observers desired2 and was not accompa-
nied by significance on the secondary outcomes. It included
benefits across the range 0 to 2 on mRS that have not
previously attracted attention.3 The distribution of National
Institutes of Health Stroke Scale (NIHSS) scores,4 which
measure neurological examination, and of the Barthel index,5
which measures activities of daily living, both showed similar
trends to improvement, although differences were not signif-
icant at 90 days. However, variability in these latter scores is
greater, and the mRs6 has become the preferred end point for
acute stroke trials.7–9 Furthermore, stroke is a devastating
condition associated with vast economic cost,10 and few
patients are able to receive thrombolytic therapy. Because of
this, modestly effective treatments may offer substantial
clinical and economic benefits when delivered to a high
proportion of patients.
Two important questions therefore arise: 1) How meaning-
ful is improvement in mRS scores at 90 days in terms of
social and economic cost? 2) In terms of resource utilization,
are day 90 mRS scores a more robust measure than NIHSS
and Barthel index scores?
Data on these 2 questions are limited. Previous work
suggests that mRS categories are clinically distinct and are
meaningful to both patients and drug-regulatory authorities.11
Higher economic costs have been associated with higher
disability levels on discharge as measured by the Rankin
scale.12–14 However, analyses have been dichotomized and
based on crude splits in mRs score disregarding information
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about any difference in costs associated with Rankin catego-
ries 0 to 1 and 3 to 4 for example. Furthermore, the time of
Rankin assessment in these studies was typically at discharge
rather than after a predetermined interval, biasing the esti-
mates and rendering extrapolation to trial data difficult.
Attempts to link resource use to Barthel index scores have
yielded even weaker associations.14–16 Equally, the Barthel
index has recently been criticized as a trial outcome measure
on grounds of its U-shaped distribution and ceiling effect
both of which render it less sensitive to drug treatment
effects.7,9 The NIHSS was designed to assess severity at trial
entry and not as an outcome measure.4 The scoring rules for
NIHSS are complex and restrictive. Patients who learn to live
with their disability scored poorly on NIHSS, although their
functional outcome measures improve. Patients who die of
unrelated causes are awarded the theoretically worst possible
score of 42, producing a bimodal and skewed distribution of
“change” scores when compared with baseline stroke sever-
ity. This undermines the very attraction of such comparisons
with baseline severity. Thus, the NIHSS score is informative
early after stroke, but when correctly scored, it poorly reflects
later outcome and, as yet, no link has been made between
change in NIHSS score and socioeconomic costs.
We hypothesized that by using records of resource use
from GAIN International,17 we would be able to demonstrate
that the healthcare costs associated with stroke vary accord-
ing to the mRS category achieved by 90 days. Demonstration
of such differences would inform interpretation of future
acute stroke trials. We further hypothesized that if mRS is a
more meaningful outcome measure than Barthel index or
NIHSS, then it would exhibit the strongest association with
healthcare costs.
Methods
We extracted and analyzed data from original records of the GAIN
International trial conducted in 1998 to 1999 and first reported in
2000. GAIN was a multicenter randomized, double-blind, placebo-
controlled trial of gavestinel after acute stroke. Patients were aged
greater than 18 years old with symptoms of acute stroke, including
limb weakness, who were previously independent and were random-
ized and treated within 6 hours of onset of stroke. Data extraction
and preparation for analysis were performed by 2 researchers (T.P.C.
and J.S.L.). Checks of resource use validity were undertaken by
reference to vital status records and functional outcomes.
Collection of Outcome Data
In GAIN, a trial investigating a neuroprotective compound, mRS,
Barthel index, and NIHSS scores were gathered at 1 month and 3
months from recruitment. Outcomes on mRS were assessed by local
observers according to a standard scoring system. No formal training
or certification was offered. To assist consistency, observers were
offered advice on scoring of Barthel index in the form of a video
demonstration but no certification procedure was in place. All
observers had been trained and were certified in use of the NIHSS
scoring system.
Collection of Resource Use Data
Resource use was recorded by trial staff at the 90-day follow-up visit
based on interviews with patients or their relatives or caregivers and
on review of hospital records. In particular, detailed data regarding
duration of hospitalization or time spent in nursing facilities was
gathered. Hospital bed occupancy was recorded in 6 categories:
emergency room, intensive care, high dependency, general ward,
rehabilitation unit, or undefined. Nonhospital placement postdis-
charge was also collected in 6 categories: own home, relative’s
home, intermediate-care facility, nursing/convalescence home, reha-
bilitation facility, or undefined. For the purposes of this analysis, all
high-dependency and medical bed-days were grouped together and
considered separately from days spent in nursing or institutional
residential care. Days spent in the patient’s own home were grouped
together with time spent in a relative’s home; the remainder was
classed as intermediate care. Length of stay was defined as the total
time in the hospital and intermediate or nursing/institutional care (all
places except the patient’s or a relative’s home).
Costs of hospital bed occupancy were taken from published
Scottish Health Service statistics for 2005 (£207 per day for hospital
care [or $408]).18 Costs of subsequent institutional or nursing home
care were based on £350 per week (or $689).19 No additional cost
was ascribed to care in the patient’s own or a relative’s home.
Only outcomes actually recorded at 907 days were used; missing
data were not imputed. Resource use was censored at 90 days. When
final follow up occurred earlier than 83 days in a patient who
survived past 90 days, last known placement was extrapolated to 90
days; patients in whom dates of placement were not recorded were
excluded from analysis. Deaths within 90 days were excluded from
the primary statistical analysis on the grounds that resource use
would inevitably be lower and that death is the least desirable health
state; however, data are shown for completeness.
Statistical Methods
One-way ANOVA was used to assess outcome-related trends in
resource use or costs for mRs scores, Barthel index, and NIHSS
scores. After significant ANOVA results, adjacent categories of
each scale were compared by Bonferroni testing. Analyses were
conducted using StatsDirect statistical software version 2.4.5
(StatsDirect Ltd).
Results
Seventeen hundred eighty-eight patients were included within
the intent-to-treat analysis of GAIN international of whom 56
withdrew from the study before 90 days for reasons other than
death. Incomplete data on resource use or final outcome
scores were available for a further 15 patients, leaving 1717
in our analysis population. Mean age (SD) was 69.712.2
years. Mean baseline NIHSS score was 13.16.2 points.
Seven hundred thirty-seven patients (42.9%) were female and
321 (18.7%) had primary intracerebral hemorrhage. Overall,
our population spent a mean of 28 days in the hospital, 17
days in intermediate institutional care, and 31 days in domes-
tic premises.
Length of stay was strongly associated with final mRS score
and with Barthel index category trichotomized into 0 to 55, 60 to
90, and 95 to 100. All categories of mRS significantly differed
from their neighbor apart from mRS 4 and 5, which were
indistinguishable (Figure 1; Table). In-hospital stay was greater
for mRS category 5, however, and when estimated costs were
included in the model, mRS 5 was found to consume signifi-
cantly more resource than mRS 4 (Table).
Length of stay for Barthel categories could only be
distinguished across the Barthel range 90 to 95–100 with
other categories contributing little useful discriminating in-
formation (Figure 2). Costs could be distinguished only
between Barthel 100 and 95.
Length of stay was significantly associated with 90-day
total NIHSS score, but between-category differences were
present only across the NIHSS ranges 0 to 1 and 4 to 5
(Figure 3) and only categories 0 to 1 could be distinguished
1894 Stroke June 2007
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
with regard to estimated cost. When the change in NIHSS
score from baseline was examined (ie, 90-day score minus
baseline score), no significant differences were found and
results showed considerable scatter (data not shown).
In total, the mean 90-day cost of stroke, excluding specific
rehabilitation costs, was £66035424.
Discussion
We have found that a significant and graded relationship
exists between 90-day mRS score and hospital, intermediate
or institutional care bed occupancy, confirming that even
short-term costs are substantially affected by the degree of
recovery at 3 months after stroke. When translated into
estimated care costs, excluding specific rehabilitation input,
we have found that each increment in mRS score adds
significantly to the 90-day cost of care. We can speculate that
such differences will accumulate substantially through time
over longer-term follow up.
We have demonstrated that certain categories on Barthel
index are also associated with changing bed occupancy and
cost but that the relationship is not graded across the entire
scale as it is with mRS. Apart from the range 90 to 100,
Figure 1. A, Length of stay during first
90 days after acute stroke according to
final mRS. Each category is signifi-
cantly different from its neighbor by
ANOVA (P0.0001) and subsequent
Bonferroni testing (all P0.0005),
except that mRS categories 4 and 5
were not significantly different. Box
plots represent the minimum,
mean95% CI, and maximum duration
of institutional stay. B, Estimated cost
of institutional stay during first 90 days
after acute stroke according to final
mRS. Each category is significantly dif-
ferent from its neighbor by ANOVA
(P0.0001) and subsequent Bonferroni
testing (all P0.0005 except mRS 0
versus mRS 1 (P0.023) and mRS 2
versus mRS 3 (P0.0015). Box plots
represent the minimum, mean95%
CI, and maximum cost of institutional
stay.
Length of Stay and Estimated Costs Across the 6 mRS Categories in Survivors
mRS 0 (n197) mRS 1 (n268) mRS 2 (n205) mRS 3 (n214) mRS 4 (n366) mRS 5
Median, mean LOS 9, 17 17, 25‡ 37, 44‡ 64, 58‡ 90, 79‡ 90, 81
Mean hospital: intermediate LOS 14: 3 18: 7 27: 17 32: 26 43: 36 55: 26
Estimated costs: 95% CI 2493 to 3412 3369 to 4479* 5784 to 7008‡ 7300 to 8512† 10 095 to 11 141‡ 11 772 to 13 560‡
*P0.025, †P0.005, ‡P0.0005 for difference when compared with preceding column.
LOS indicates length of stay.
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Barthel index scores offer little useful information in this
regard. Our study has only examined resource use in terms
of bed occupancy over the first 90 days. It remains possible
that Barthel index scores would be more informative in
predicting longer-term use of other types of support
services.
The GAIN International trial included a wide range of
patients considered to be representative of the usual acute
stroke population. The data on resource use were collected
during end point assessment and were monitored and verified
against source data. A limited number of patients withdrew
consent for follow up and there were few missing observa-
tions. These were not of a frequency or nature that would
influence the conclusions. International variation in clinical
practice will influence total length of stay and the proportion
in various categories. Costs of hospital and intermediate
institutional care will also vary. We have therefore chosen not
to subdivide types of hospital or intermediate care in our
analysis, but have supplied sufficient data within our report
for reinterpretation based on alternative estimates of costs.
We used £207 as our cost for hospital care, which was based
on the cost of a medical day bed. Total costs will have been
underestimated for those who required high dependency or
intensive care, but this will only have attenuated the relation-
ship we have seen. Costs in Scotland may be lower than in
other countries, in particular the United States, but the
proportional changes should be similar. The definitions used
also explain why the lengths of stay appear long. For
example, a median and mean length of stay of 9 and 17 days,
respectively, was seen in those with a day 90 mRS of 0.
Importantly, these figures include stays in rehabilitation units
and therefore provide a more meaningful measure of impact
and cost of stroke than, for example, duration of stay in acute
medical or high-dependency beds; the time taken to attain full
recovery is often underestimated.
Previous studies have shown a relationship between re-
source utilization and level of handicap, in particular when
the mRs is used. However, these were limited in size and
follow-up periods were uncontrolled. Ninety days has be-
come the standard time for end point assessment in acute
stroke trials. Furthermore, prior reports typically divided their
populations for these analyses into Rankin 0 to 2 versus 3 to
6 disregarding information about the costs associated with
individual Rankin categories, especially in the range 0 to 2.3
We elected not to do this in our study. Also, direct compar-
isons between different measures of functional outcome have
not been made with regard to resource use. Establishing the
relationship between 90-day outcome and resource use and
exploring whether one outcome measure is more clearly
associated is of direct relevance to, and would aid interpre-
tation of, clinical trial data.
We have now shown in an independent population that
there are significant differences in resource use in terms of
institutional bed occupancy and estimated institutional
costs that are strongly associated with mRs scores and with
each incremental increase in score, even in the range 0 to
1–2. The finding that estimated institutional care costs are
significantly related to 90-day Barthel index is not a
surprise, but the lack of a convincing graded influence of
the Barthel index may surprise proponents of the scale.
However, this has been suggested by other groups.14 –16
Our results suggest that, when compared with the mRs, the
Barthel index is less clearly related to outcomes that matter
to patients and to healthcare providers, which reaffirms the
belief that mRS outcomes and nondichotomized methods
of analysis should be used. Our results also suggest that
changes in disability level not captured by traditional
dichotomized analyses are both clinically and economi-
cally significant and that small shifts from mRs category 4
to 3 in particular are likely greatly to reduce care costs.
Because mRS categories are loosely described and because
there is variation among observers in scoring an individual
patient, further attempts to improve its reliability such as
the formal training and certification program developed in
Glasgow should be used.
It is clear from our results that “change from baseline in the
NIHSS” has serious statistical disadvantages as an outcome
measure, but an examination of the relationship between
NIHSS scores and robust measures of outcome such as
duration of care remains of interest. We find in this indepen-
dent sample that change in NIHSS score relates poorly to
duration of institutional stay over the first 90 days after stroke
and to estimated resource use. This adds to the evidence that
change in NIHSS appears to be an inappropriate end point for
acute stroke trials. Final total NIHSS score may experience
fewer disadvantages. The relation between 90-day total
NIHSS score and institutional care was statistically signifi-
Figure 2. Length of stay during first 90 days after acute
stroke according to final Barthel score. Duration of stay was
associated with Barthel index (P0.0001 by ANOVA), but on
Bonferroni testing of adjacent categories, significant differences
were found only within the range 90 to 95–100. However, if
Barthel scores were grouped (0 to 55, 60 to 90, and 95 to 100),
then each group differed significantly from its neighbor (data not
shown).
1896 Stroke June 2007
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
cant but mainly restricted to final scores in the range of 0 to
5. NIHSS therefore appears to have similar weaknesses to use
of the Barthel index.
The results of our study are widely applicable. Although
the GAIN International trial was reported 4 years ago, it
included a similar range of countries and sites, a similar
patient group, and recorded outcomes in a similar manner as
recent and ongoing trials. Also, detailed records were pro-
spectively collected regarding resource use. Clinical practice
may have changed since the GAIN trial was conducted,
especially in regard to thrombolytic therapy with recombinant
tissue-type plasminogen activator. This is likely to influence
functional outcomes but should not alter the relation among
functional recovery, bed occupancy, and associated costs. If
outcomes are improved overall by modern care, then resource
use within the first 90 days will assume even greater
relevance.
In conclusion, mRS at 90 days is strongly associated with
institutional bed occupancy over the preceding 3 months and
with estimated care costs. Each grade on the mRS carries a
different cost in terms of resource use, including the distinc-
tion between mRS 0 (no symptoms) and mRS 1 (symptoms
but no disability). The mRS is thus a useful scale to assess
outcome after acute stroke outcome and has several advan-
tages over the Barthel index or NIHSS, including its relation
to institutional resource use and discrimination.
Figure 3. Length of stay during first 90
days after acute stroke according to
final total NIHSS score. There is an
overall difference among categories by
ANOVA (P0.0001), but significant
differences between adjacent categories
were present only within the ranges 0
to 1 and 4 to 5.
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